Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study
Author: Carter, H.
Zannino, D.
John Simes, R.
Schofield, D.
Howard, K.
Zalcberg, J.
Price, T.
Tebbutt, N.
Citation: European Journal of Cancer, 2014; 50(3):535-543
Publisher: Elsevier
Issue Date: 2014
ISSN: 0959-8049
Statement of
Hannah E. Carter, Diana Zannino, R. John Simes, Deborah J. Schofield, Kirsten Howard, John R. Zalcberg, Timothy J. Price, Niall C. Tebbutt
Abstract: Abstract not available
Keywords: Cost; Effectiveness; Bevacizumab; Colorectal; Cancer; MAX
Rights: Copyright © 2013 Elsevier Ltd. All rights reserved.
DOI: 10.1016/j.ejca.2013.09.028
Appears in Collections:Aurora harvest 2
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.